Potential Roles of Myeloid Differentiation Factor 2 on Neuroinflammation and Its Possible Interventions
- 15 August 2020
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 57 (11), 4825-4844
- https://doi.org/10.1007/s12035-020-02066-2
Abstract
Neuroinflammation is the primary response by immune cells in the nervous system to protect against infection. Chronic and uncontrolled neuroinflammation triggers neuronal injury and neuronal death resulting in a variety of neurodegenerative disorders. Therefore, fine tuning of the immune response in the nervous system is now extensively considered as a potential therapeutic intervention for those diseases. The immune cells of the nervous system express Toll-like receptor 4 (TLR4) together with myeloid differentiation factor 2 (MD-2) to protect against the pathogens. Over the last 10 years, antagonists targeting the functional domains of MD-2 have become attractive pharmacological intervention strategies in pre-clinical studies into neuroinflammation and its associated brain pathologies. This review aims to summarize and discuss the roles of TLR4-MD-2 signaling pathway activation in various models of neuroinflammation. This review article also highlights the studies reporting the effect of MD-2 antagonists on neuroinflammation in in vitro and in vivo studies.Keywords
Funding Information
- Thailand Science Research and Innovation Grant (DBG6280006)
- National Research Council of Thailand (Senior Research Scholar grant)
- Thailand Research Fund (RSA6180071)
- Chiang Mai University (CMU excellent center award)
- National Science and Technology Development Agency (NSTDA research chair grant)
This publication has 119 references indexed in Scilit:
- Angiotensin II AT1 receptor blockers as treatments for inflammatory brain disordersClinical Science, 2012
- Dendritic cell control of tolerogenic responsesImmunological Reviews, 2011
- Toll‐like receptor 4 in CNS pathologiesJournal of Neurochemistry, 2010
- Minimal penetration of lipopolysaccharide across the murine blood–brain barrierBrain, Behavior, and Immunity, 2009
- Lipopolysaccharide alters the blood–brain barrier transport of amyloid β protein: A mechanism for inflammation in the progression of Alzheimer’s diseaseBrain, Behavior, and Immunity, 2009
- Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trialBMJ, 2008
- Systemic LPS causes chronic neuroinflammation and progressive neurodegenerationGlia, 2007
- The cellular response in neuroinflammation: The role of leukocytes, microglia and astrocytes in neuronal death and survivalClinical Neuroscience Research, 2006
- Toll-like receptor signallingNature Reviews Immunology, 2004
- Neuroinflammation in Alzheimer's disease and prion diseaseGlia, 2002